Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
GEHC vs SYK: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
GEHC Captures Overall Composite Edge (36.0 SELL vs 46.5 HOLD), While SYK Leads 5–1 on Growth & Valuation Pillars
GEHC Overall Winner
6-Pillar Tally: GEHC 1 – 5 SYK
Matrix Metrics: GEHC 5 – 5 SYK
As of Nov 16, 2026, GE HealthCare Technologies Inc. (GEHC) captures the overall head-to-head institutional edge over Stryker Corporation (SYK) on higher Unified Composite conviction (36.0/100 SELL vs. 46.5/100 HOLD) after splitting the core matrix 5–5 (led by Valuation Multiples), while SYK wins 5–1 across the 6-pillar growth and valuation breakdown. GEHC trades at $83.19 (15.1x Forward P/E, 13.8% operating margin) versus SYK at $310.79 (19.0x Forward P/E, 24.0% operating margin).
- Composite vs. Pillar Nuance: While SYK currently prints a higher short-term Unified Composite Score (46.5/100 HOLD vs. GEHC 36.0/100 SELL), GEHC captures the overall institutional head-to-head verdict (5–5 matrix metrics and 1–5 across the 6 pillars) due to superior fundamental profitability (13.8% vs. 24.0% operating margin) and revenue trajectory (+7.2% vs. +7.6% YoY).
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About GEHC vs SYK
GEHC
Head-to-Head Winner
GE HealthCare Technologies Inc. Common Stock
$83.19
+0.2% 1D
Market Cap
$37.0B
TTM Revenue
$21.6B
Forward P/E
15.1x
Beta / 30D Vol
0.53β · 39% Vol
Unified Composite Score
36.0
SELL
Tech 20.0
Fund 32.0
Flow 58.0
Mom 40.0
Weinstein Technical Phase
Markup · Hold / add on dips
SYK
Stryker Corporation
$310.79
+0.37% 1D
Market Cap
$118.9B
TTM Revenue
$26.3B
Forward P/E
19.0x
Beta / 30D Vol
0.22β · 50% Vol
Unified Composite Score
46.5
HOLD
Tech 37.0
Fund 49.0
Flow 58.0
Mom 60.0
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (GEHC 1 – 5 SYK)
1. Valuation Multiples
GEHC
Forward P/E
15.1x
19.0x
Trailing P/E
17.3x
33.3x
PEG Ratio
2.21x
1.54x
EV / Revenue
2.1x
5.0x
2. Growth & Scale
SYK
Revenue Growth (YoY)
+7.2%
+7.6%
Earnings Growth (YoY)
+39.0%
-11.7%
TTM Revenue (USD)
$21.6B
$26.3B
Market Cap
$37.0B
$118.9B
3. Profitability & Quality
SYK
Gross Margin
39.3%
65.7%
Operating Margin
13.8%
24.0%
Net Profit Margin
10.0%
13.8%
Return on Equity (ROE)
20.0%
16.0%
4. Balance Sheet & Cash Flow
SYK
Cash Generation (TTM)
$1.89B
$4.57B
Cash Flow Margin
8.7%
17.4%
Net Cash / Leverage
$7.58B Net Debt (0.90x D/E)
$11.7B Net Debt (0.64x D/E)
Dividend Yield
0.18%
1.10%
5. Options & Positioning
SYK
Options Structure Phase
SURGE
SURGE
Current IV / %ile
47.7% (6th %ile)
28.1% (5th %ile)
Put/Call OI Skew
0.38x (Call-Skewed)
0.30x (Call-Skewed)
OBV Trend / Tech Phase
DISTRIBUTION · Markup
DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat
SYK
OpEx & R&D Intensity
25.5% of Rev ($5.52B)
41.7% of Rev ($11.0B)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Scale & Operating Efficiency Moat
Concentrated Oligopoly Moat
Supply-Chain Role
Medical Devices Operator
Medical Devices Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: GEHC (5) vs SYK (5)| Institutional Metric | GEHC | SYK | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $37.0B | $118.9B | SYK | |
| Trailing P/E Ratio | 17.3x | 33.3x | GEHC | |
| Forward P/E Ratio | 15.1x | 19.0x | GEHC | |
| Revenue Growth (YoY) | +7.2% | +7.6% | SYK | |
| Operating Margin (TTM) | 13.8% | 24.0% | SYK | |
| Net Profit Margin | 10.0% | 13.8% | SYK | |
| Return on Equity (ROE) | 20.0% | 16.0% | GEHC | |
| 52-Week Range Position | 79% ($59–$90) | 36% ($267–$389) | GEHC | |
| Beta / 30D Volatility | 0.53β · 39% Vol | 0.22β · 50% Vol | GEHC | |
| Unified Institutional Score | 36.0 / 100 (SELL) | 46.5 / 100 (HOLD) | SYK | |
| Trailing 12M Revenue (USD) | $21.6B | $26.3B | Scale | |
| Gross Profit Margin (TTM) | 39.3% | 65.7% | Quality | |
| PEG Ratio & EV / Revenue | 2.21x PEG · 2.1x EV/Rev | 1.54x PEG · 5.0x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | $1.89B ($7.58B Net Debt (0.90x D/E)) | $4.57B ($11.7B Net Debt (0.64x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
GEHC +14.1 pp
3M Horizon
GEHC +20.74 pp
6M Horizon
GEHC +36.02 pp
1Y Horizon
GEHC +29.23 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | GEHC Revenue | SYK Revenue | GEHC Op. Margin | SYK Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | N/A | $13.6B | N/A | 18.7% | SYK |
| FY2019 | N/A | $14.9B | N/A | 18.2% | SYK |
| FY2020 | N/A | $14.3B | N/A | 15.5% | SYK |
| FY2021 | $17.6B | $17.1B | 15.9% | 15.1% | GEHC |
| FY2022 | $18.3B | $18.4B | 13.8% | 15.4% | SYK |
| FY2023 | $19.6B | $20.5B | 12.5% | 19.0% | SYK |
| FY2024 | $19.7B | $22.6B | 13.3% | 16.3% | SYK |
| FY2025 | $20.6B | $25.1B | 13.4% | 19.5% | SYK |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
GEHC
SURGE
Current IV
47.7%
IV Percentile
6th %ile
Put/Call OI Skew
0.38x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BEARISH
OBV Flow
DISTRIBUTION
Exact GEHC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
SYK
SURGE
Current IV
28.1%
IV Percentile
5th %ile
Put/Call OI Skew
0.30x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BEARISH
OBV Flow
DISTRIBUTION
Exact SYK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
GEHC Moat Profile
Scale & Operating Efficiency Moat
Medical Devices Operator
OpEx & R&D Reinvestment
25.5% of Rev ($5.52B)
90D Engineering Disclosures
0 Published
SYK Moat Profile
Concentrated Oligopoly Moat
Medical Devices Operator
OpEx & R&D Reinvestment
41.7% of Rev ($11.0B)
90D Engineering Disclosures
0 Published · Surgical Robotics
Investor FAQ GEHC vs SYK Key Questions & Quantitative Answers
As of Nov 16, 2026, GE HealthCare Technologies Inc. (GEHC) captures the overall head-to-head institutional edge over Stryker Corporation (SYK) on higher Unified Composite conviction (36.0/100 SELL vs. 46.5/100 HOLD) after splitting the core matrix 5–5 (led by Valuation Multiples), while SYK wins 5–1 across the 6-pillar growth and valuation breakdown. GEHC trades at $83.19 (15.1x Forward P/E, 13.8% operating margin) versus SYK at $310.79 (19.0x Forward P/E, 24.0% operating margin). Composite vs. Pillar Nuance: While SYK currently prints a higher short-term Unified Composite Score (46.5/100 HOLD vs. GEHC 36.0/100 SELL), GEHC captures the overall institutional head-to-head verdict (5–5 matrix metrics and 1–5 across the 6 pillars) due to superior fundamental profitability (13.8% vs. 24.0% operating margin) and revenue trajectory (+7.2% vs. +7.6% YoY).
SYK leads the Growth & Scale pillar: GEHC posts +7.2% YoY revenue growth and +39.0% YoY earnings growth on $21.6B TTM revenue (39.3% gross margin, 13.8% operating margin), compared with SYK at +7.6% YoY revenue growth and -11.7% YoY earnings growth on $26.3B TTM revenue (65.7% gross margin, 24.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), GEHC cumulative revenue shifted +17.2% while SYK shifted +84.7%. In operating R&D and SG&A reinvestment, GEHC deploys 25.5% of Rev ($5.52B) (0 90-day corporate R&D disclosures) versus 41.7% of Rev ($11.0B) (0 disclosures) for SYK.
GEHC screens cheaper on headline valuation multiples. GEHC trades at 15.1x Forward P/E, 17.3x Trailing P/E, 2.21x PEG, and 2.1x EV/Revenue (8.7% FCF margin), whereas SYK trades at 19.0x Forward P/E, 33.3x Trailing P/E, 1.54x PEG, and 5.0x EV/Revenue (17.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GEHC (20.0% ROE) versus SYK (16.0% ROE) capital efficiency.
In options market volatility and institutional positioning, GEHC carries 47.7% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.38x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.53β · 39% Vol realized risk). By comparison, SYK carries 28.1% implied volatility (5th %ile, Compressed (<25th %ile)), a 0.30x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.22β · 50% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
SYK vs GEHC · Reverse Pair
GEHC vs GEV
· Sector Peer
GEHC vs WAB
· Sector Peer
GEHC vs VTRS
· Sector Peer
SYK vs MDT
· Sector Peer
SYK vs BDX
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem